Dihydroergotamine
Dihydroergotamine (DFN-19) is a semisynthetic, hydrogenated ergot alkaloid. Dihydroergotamine can cause vasoconstriction by stimulating alpha-adrenergic and 5-HT2A receptors. Dihydroergotamine can be used in the research of migraine[1].
Product Specifications
CAS Number
511-12-6
Product Name Alternative
DFN-19
UNSPSC
12352005
Hazard Statement
H315-H319-H320
Target
5-HT Receptor; Adrenergic Receptor
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease; Neurological Disease
Smiles
O[C@@]([C@@](CCC1)([H])N1C2=O)(O[C@](NC([C@@H](CN(C)[C@]3([H])C4)C[C@]3([H])C5=C6C4=CNC6=CC=C5)=O)(C)C7=O)N7[C@H]2CC8=CC=CC=C8
Molecular Formula
C33H37N5O5
Molecular Weight
583.68
Precautions
P264-P280-P302+P352-P305+P351+P338-P362
References & Citations
[1]Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003 Feb;43 (2) :144-66.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
5-HT2 Receptor; α adrenergic receptor
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
KRR1, NT (KRR1, HRB2, KRR1 small subunit processome component homolog, HIV-1 Rev-binding protein 2, KRR-R motif-containing protein 1, Rev-interacting protein 1) (PE) discontinued
